Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3067PDF: 904HTML: 6616Untitled: 266Untitled: 223Untitled: 238Untitled: 253 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4998PDF: 2937HTML: 2348 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2865PDF: 1194HTML: 3312 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2991PDF: 1057HTML: 5644 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2958PDF: 1478HTML: 3099Cover Letter: 238 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3482PDF: 1529HTML: 4083 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4144PDF: 1581HTML: 9309Untitled: 308Untitled: 206Untitled: 193Untitled: 190Untitled: 207Untitled: 366 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2692PDF: 919HTML: 17602Fig1 Caligaris: 206Fig.2 Caliga: 252 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4064PDF: 1102HTML: 3901Untitled: 192Cneo. Fig.1: 129Untitled: 124Untitled: 149Untitled: 158 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3421PDF: 995HTML: 2993 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3576PDF: 1434HTML: 2724 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2628PDF: 883HTML: 9061Efremov 1: 259Efremov 2: 221 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2364PDF: 1095HTML: 2029Characteristic of study group: 225 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2336PDF: 860HTML: 1701Figure 1: 229Table 1: 241 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3203PDF: 929HTML: 7307Kost Fig1: 215Kost Fig 2: 201Kost Fig3: 208Kost Fig 4: 220Kost Fig5: 218Kost fig 6: 205 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9360PDF: 6217HTML: 88096Fig.1b: 224Fig.1c: 224Fig.2a: 207Fig.2b: 206Fig.4: 228Fig.2c: 208Fig.3: 212Tab.1: 266Tab.2: 246Tab.3: 227Tab.4: 256Fig1a: 222 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4075PDF: 785HTML: 1889 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4498PDF: 961HTML: 1362Table1: 210 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2576PDF: 825HTML: 1747 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3003PDF: 1323HTML: 2835Figure 1: 201 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
3344PDF: 1162HTML: 7748cover letter paper final AML: 245 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2759PDF: 795HTML: 2326 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2386PDF: 1368HTML: 17209Bassan Fig.1: 165Bassan Fig.2: 269Bassan Fig.4: 158Fig.3: 229 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
5122PDF: 1355HTML: 1936Untitled: 212Untitled: 199 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3611PDF: 925HTML: 1692figure 1: 192Untitled: 217 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3689PDF: 1596HTML: 4503CoverLetter: 206Figure1: 223 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
2100PDF: 980HTML: 1776Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 191 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1251PDF: 792HTML: 1532Figure 1: 223Figure 2: 218







